Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Cencora, Inc. is a global pharmaceutical solutions organization that operates primarily within the healthcare distribution and services industry. Formerly known as AmerisourceBergen, the company rebranded to Cencora in 2023 to reflect its broader role beyond traditional drug distribution. Its core business centers on the distribution of pharmaceuticals, biotechnology products, and healthcare services to a wide range of providers, manufacturers, and patients.
The company’s primary revenue driver is pharmaceutical distribution, particularly in the U.S. healthcare market, where it serves retail pharmacies, hospital systems, physician practices, and long-term care facilities. Cencora is strategically positioned as one of the largest pharmaceutical distributors in North America, with scale, regulatory expertise, and supply chain infrastructure serving as key competitive advantages. Founded in 2001 through the merger of Bergen Brunswig and AmeriSource Health, the company expanded organically and through acquisitions, becoming a critical intermediary in the global pharmaceutical supply chain.
Business Operations
Cencora operates through two primary business segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment accounts for the majority of revenue and focuses on pharmaceutical distribution, specialty drug services, and related logistics and reimbursement support. The company distributes branded, generic, and specialty drugs, including complex biologics, leveraging extensive warehousing and distribution assets across the United States.
The International Healthcare Solutions segment provides pharmaceutical distribution, consulting, and commercialization services outside the U.S., particularly to biopharmaceutical manufacturers. Cencora controls specialized service platforms supporting clinical trial logistics, market access, and patient support programs. Its operations include wholly owned subsidiaries such as World Courier, Alliance Healthcare, and PharMEDium, which extend its capabilities into specialty logistics, European distribution, and compounded sterile preparations.
Strategic Position & Investments
Cencora’s strategic direction emphasizes growth in specialty pharmaceuticals, manufacturer services, and global healthcare solutions. The company has invested heavily in expanding its specialty drug infrastructure and data-driven services to support biopharmaceutical innovation, particularly in oncology, rare diseases, and cell and gene therapies. These areas are viewed as long-term growth drivers due to their complexity and higher service requirements.
Notable strategic investments include the acquisition of Alliance Healthcare assets to strengthen European pharmaceutical distribution and the continued expansion of World Courier to support global clinical trials and advanced therapies. Cencora also maintains equity investments and long-term strategic relationships with pharmaceutical manufacturers and healthcare service providers. Its portfolio increasingly reflects exposure to emerging healthcare technologies, including personalized medicine and advanced biologics.
Geographic Footprint
Cencora is headquartered in North America, with its principal executive offices in Conshohocken, Pennsylvania. The company has a dominant operational presence in the United States, where the majority of its revenue is generated through domestic pharmaceutical distribution and healthcare services.
Internationally, Cencora operates across Europe, Asia-Pacific, Latin America, and select markets in Africa. Through subsidiaries such as Alliance Healthcare and World Courier, the company maintains distribution centers, logistics hubs, and service operations in more than 50 countries. This global footprint enables Cencora to support multinational pharmaceutical manufacturers and healthcare systems with end-to-end supply chain and commercialization solutions.
Leadership & Governance
Cencora is led by an executive team with deep experience in pharmaceutical distribution, healthcare services, and global operations. The leadership emphasizes operational excellence, regulatory compliance, and long-term value creation through strategic partnerships and patient-centered solutions. Governance is overseen by a board of directors with backgrounds in healthcare, finance, and global business.
Key executives include:
- Steven H. Collis – Chairman, President, and Chief Executive Officer
- James F. Cleary – Executive Vice President and Chief Financial Officer
- Elizabeth S. Campbell – Executive Vice President and Chief Strategy Officer
- Robert P. Mauch – Executive Vice President and President, U.S. Healthcare Solutions
- John H. Chou – Executive Vice President and President, International Healthcare Solutions
The leadership team’s strategic vision centers on expanding global healthcare access, supporting pharmaceutical innovation, and strengthening Cencora’s role as a critical partner across the healthcare ecosystem.